ABVC BioPharma (NASDAQ:ABVC – Get Free Report) and Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Profitability
This table compares ABVC BioPharma and Eledon Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ABVC BioPharma | -8,363.97% | -139.97% | -75.61% |
| Eledon Pharmaceuticals | N/A | -233.17% | -45.44% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for ABVC BioPharma and Eledon Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ABVC BioPharma | 0 | 0 | 0 | 0 | N/A |
| Eledon Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Institutional and Insider Ownership
11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 11.9% of ABVC BioPharma shares are held by company insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares ABVC BioPharma and Eledon Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ABVC BioPharma | $136,396.00 | 45.43 | -$10.52 million | ($2.25) | -0.25 |
| Eledon Pharmaceuticals | N/A | N/A | -$116.54 million | ($1.38) | -1.90 |
ABVC BioPharma has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
ABVC BioPharma has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
Summary
Eledon Pharmaceuticals beats ABVC BioPharma on 7 of the 11 factors compared between the two stocks.
About ABVC BioPharma
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
